Recce Pharmaceuticals Completes First Cohort Dosing of Phase l/ll UTI Rapid Infusion Clinical Trial at Scientia Clinical Research
August 01, 2023 08:00 ET
|
Recce Pharmaceuticals
Cohort dosing at Scientia Clinical Research has been completed ahead of scheduleDemonstrated RECCE® 327 (R327) to be safe and well-tolerated in male and female subjects at two faster infusion rates of...
Recce Pharmaceuticals to Present at the 2023 Military Health System Research Symposium (MHSRS)
July 31, 2023 08:00 ET
|
Recce Pharmaceuticals
SYDNEY, Australia, July 31, 2023 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) (the Company), the Company developing a new class of synthetic anti-infectives, today announced a...
Recce Pharmaceuticals Doses Subjects in Rapid Infusion Phase I/II UTI Clinical Trial of RECCE® 327 at Scientia Clinical Research
July 26, 2023 08:00 ET
|
Recce Pharmaceuticals
Dosing at Scientia Clinical Research has commenced with first male and female subjects dosed ahead of scheduleSubjects who received RECCE® 327 (R327) were dosed at faster infusion rates than subjects...
Recce Pharmaceuticals Achieves Positive Phase I Clinical Trial Data of RECCE® 327 as an Intravenous Infusion Formulation
July 20, 2023 08:25 ET
|
Recce Pharmaceuticals
Highlights: Independent examiners confirm Phase I study of RECCE® 327 (R327) in 80 human subjects across eight cohorts achieved all primary study endpoints, met international regulatory standards,...
Recce Pharmaceuticals Receives A$801,604 Research and Development (R&D) Rebate Advance
July 13, 2023 08:00 ET
|
Recce Pharmaceuticals
SYDNEY, Australia, July 13, 2023 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) (the Company), the Company developing a new class of synthetic anti-infectives, is pleased to...
Recce Pharmaceuticals Announces First Cohort Dosed in RECCE® 327 Rapid Infusion Phase I/II Urinary Tract Infection (UTI) Clinical Trial
July 11, 2023 08:00 ET
|
Recce Pharmaceuticals
Highlights: First cohort in Phase I/II urinary tract infection (UTI) rapid infusion intravenous (IV) study successfully dosed 2,500mg of RECCE® 327 (R327), resulting in high peak urine...
Recce Pharmaceuticals Announces Change of Director’s Interest Notices – James Graham
June 28, 2023 08:00 ET
|
Recce Pharmaceuticals
SYDNEY, Australia, June 28, 2023 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Limited (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, is pleased to provide a...
Recce Pharmaceuticals to be Granted New Anti-Viral Patent in Australia for RECCE® Anti-Infectives
April 11, 2023 08:00 ET
|
Recce Pharmaceuticals
SYDNEY, Australia, April 11, 2023 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, is pleased to announce the...
Recce Pharmaceuticals Receives Further A$973,144 Research and Development (R&D) Advance
April 06, 2023 08:00 ET
|
Recce Pharmaceuticals
SYDNEY, Australia, April 06, 2023 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) (the Company), the Company developing a new class of synthetic anti-infectives, is pleased to...
Recce Pharmaceuticals Announces RECCE® Trademark Registered in Hong Kong, Strengthening Global IP Portfolio
February 03, 2023 07:59 ET
|
Recce Pharmaceuticals
SYDNEY, Australia, Feb. 03, 2023 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) (the Company), the Company developing a new class of synthetic anti-infectives, today announced...